Drug Trial Radar · NCT05248880
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
309
Actual
Start
Mar 8, 2022
Primary completion
Feb 1, 2023
Study completion Feb 1, 2023
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in toxin-naïve participants with moderate to severe GL. This is a 12 week study in which eligible subjects will be enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants are randomly assigned to receive AGN-151586 or placebo. There is 1 in a 4 chance that participants will receive placebo. Around 300 adult participants with moderate to severe GL will be enrolled in the study in approximately 15 sites. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive an open-label treatment of AGN-151586 during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
Intramuscular Injection
PlaceboDrug
Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]Time frame: Baseline, Day 7 (Double-blind period)
- Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind period)
- Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]Time frame: Baseline, Day 7 (Double-blind Period)
- Number of Participants With Adverse EventsTime frame: From time of informed consent to end of study; median time on follow-up was 85 days for all groups.
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Clear Dermatology & Aesthetics Center /ID# 238990
Scottsdale, Arizona
Steve Yoelin MD Medical Associate Inc /ID# 243197
Newport Beach, California
Marcus Medical Spa /ID# 241703
Redondo Beach, California
DMR Research PLLC /ID# 239061
Westport, Connecticut
Duplicate_Kavali Plastic Surgery and Skin Renewal Center /ID# 244808
Atlanta, Georgia
DelRicht Research /ID# 244890
Baton Rouge, Louisiana
Maryland Dermatology Laser, Skin, & Vein Institute /ID# 239067
Hunt Valley, Maryland
WDC Cosmetic and Research, PLLC /ID# 233935
Wilmington, North Carolina
Clinical Research Center of the Carolinas /ID# 239064
Charleston, South Carolina
Duplicate_Austin Institute for Clinical Research /ID# 238989
Pflugerville, Texas
Kalo Clinical Research /ID# 247279
West Valley City, Utah
SkinDC /ID# 238988
Arlington, Virginia
YVR Aesthetics Training & Study Centre /ID# 241858
Vancouver, British Columbia, Canada
Pacific Derm /ID# 239654
Vancouver, British Columbia, Canada
Dr Melinda Gooderham Medicine Profession /ID# 239657
Cobourg, Ontario, Canada
The Centre for Clinical Trials /ID# 245873
Oakville, Ontario, Canada
Clinique D /ID# 239653
Laval, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.